This single-center, prospective, observational study was performed in ICU of Guangdong Provincial People’s Hospital from July 2018 to January 2020. The inclusion criteria were applied: age ≥18 years, receiving teicoplanin (Targocid, Sanofi Co, Guangdong, China) intravenously, diagnosed or suspected clinically with Gram-positive infections. Exclusion criteria were patients who lacked any of the demographic and laboratory data described below. Demographic and clinical characteristics were collected including age, sex, body weight, serum creatinine concentrations (Scr), serum albumin concentrations (ALB). Creatinine clearance (Ccr) was calculated by the Cockcroft-Gault formula. The estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.20 (link) In addition, other clinical information including teicoplanin doses and dosing intervals, each time point of sample collection, the continuous renal replacement therapy (CRRT) status, baseline acute physiology and chronic health evaluation (APACHE) II scores were also recorded.
Targocid
Manufactured by Sanofi
Sourced in China
Targocid is a laboratory equipment product manufactured by Sanofi. It is used for in-vitro diagnostic purposes. The core function of Targocid is to facilitate the detection and identification of specific biological targets within a sample.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using targocid
1
Teicoplanin Pharmacokinetics in ICU Patients
2
Pediatric Teicoplanin Pharmacokinetics Study
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This was a retrospective PK study performed in two hospitals in China according to the principles of the current Declaration of Helsinki and Good Clinical Practice (Hospital 1: the First Affiliated Hospital of Xi’an Jiaotong University; Hospital 2: the Affiliated Children Hospital of Xi’an Jiaotong University). The protocol was approved by the institutional review board of each study site (No.XJTU1AF2017LSK-28). All patients aged 1 month to 18 years old receiving teicoplanin (Targocid, Sanofi-Aventis) for proven or suspected MRSA infection were selected for the study over 33-month period (March 2017 and November 2019). Children were excluded if a complete teicoplanin dosing history or precise sampling time was not available. The demographic variables with potential impact on the PK of teicoplanin and details of teicoplanin administration (dose and infusion start and stop times) were extracted from medical records retrospectively by a trained research assistant. If serum creatinine (SCr) readings were unavailable around the teicoplanin dosing (±48 h), the closest available SCr reading would be imputed. Creatinine clearance (CLcr) was estimated by Cockcroft formula: CLcr = (140 – age (years)) ×weight (WT, kg) × 0.85 (if female)/0.818 × SCr (μmol/L), instead of Schwartz formula due to the lack of height data in most children (Cockcroft and Gault, 1976 (link)).
3
Aspergillus Infection in Neutropenic Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female Lewis rats of 2–3 months age were treated with the immunosuppressant cyclophosphamide (Endoxan, Bayter, 75 mg/kg i.p.) 5 days and 1 day before A. fumigatus inoculation to induce neutropenia. To avoid bacterial superinfections, animals repeatedly (5 days, 1 day before and on the day of inoculation) received antibiotic teicoplanin (Targocid, Sanofi, 35 mg/kg–5 days before i.m. or 25 mg/kg i.m.–1 day before and on the day of inoculation) and additional antibiotics were administered by drinking water (Ciprofloxacin, 2 mM, Polymyxin E, Colomycin, 0.1 mM) for the duration of the experiment. Fungal infection was established by intratracheal application of 100 µL of A. fumigatus spores (109 CFU/mL A. fumigatus 1059 CCF) using TELE PACK VET X LED system equipped with a flexible endoscope (Karl Stroz GmbH & Co. KG, Tuttlingen, Germany) only [24 (link)].
4
Aspergillosis Induction in Immunosuppressed Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Additionally, 2–3-month-old female Lewis rats were treated with the immunosuppressant cyclophosphamide (Endoxan, Baxter, Prague, Czech Republic, 75 mg/kg i.p.) 5 days and 1 day before they were infected with A. fumigatus, to induce neutropenia. The animals repeatedly received (5 days, 1 day before, and on the day of inoculation) the antibiotic teicoplanin (Targocid, Sanofi-Aventis, Prague, Czech Republic, 35 mg/kg—5 days before i.m., or 25 mg/kg i.m.—1 day before and on the day of inoculation) to avoid bacterial superinfections, and additional antibiotics were administered by drinking water (Ciprofloxacin, Fresenius Kabi, Prague, Czech Republic, 2 mM, Colomycin, Teva, Prague, Czech Republic, 0.1 mM) for the duration of the experiment. Infection in the lung was established by intratracheal inoculation of 100 μL of A. fumigatus spores (109 CFU/mL A. fumigatus ATCC 46645) using TELE PACK VET X LED system equipped with a flexible endoscope (Karl Stroz GmbH and Co. KG, Tuttlingen, Germany) [36 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!